Like a blocked water line, obstructions in the blood vessels of the human circulatory system can cause serious problems. This is especially the case with upper vena cava syndrome (SVCS), in which partially or completely prevented oxygen-returning blood from returning from the head, upper chest, and arms is prevented from reaching the heart. The result, however, is far more serious than the annoyance of the low water pressure of a clogged pipe; the SVCS requires immediate attention.
Each year, about 15,000 people in the United States are affected by SVCS, whose symptoms include facial swelling, shortness of breath, chest pain, mental confusion, and sometimes coma. A tumor that compresses the vessel of the superior vena cava is the most common cause, but the disease can also result from intravascular devices, such as catheters and pacemakers, that can compress or clog the vessel.
Historically, radiotherapy, aimed at killing tumor cells, was the treatment of choice for SVCS. But in recent decades, the minimally invasive endovascular stent, in which a tubular support is placed inside the collapsed or clogged vessel, has become the preferred option of care. It’s unclear if this is the best option, but now, a new analysis by researchers at Temple University’s Lewis Katz School of Medicine shows that endovascular therapy is currently the safest and safest. effective treatment for SVCS.
“The endovascular stent has emerged as a first-line treatment for SVCS,” said Riyaz Bashir, MD, FACC, RVT, professor of medicine at Lewis Katz School of Medicine at Temple University and director of Vascular and Endovascular Medicine. of Temple University Hospital. “But until our recent work there had been none systematic review was carried out to assess the actual success rate of the stenting “.
The review by Dr. Bashir and colleagues was published online in the journal on June 28th Clinical Medicine.
Team analysis was conducted by first conducting a systematic review of medical literature databases such as PubMed and Cochrane Library. Collaborator Stephanie Clare Roth, MLIS, a librarian for research and biomedical services at the Ginsburg Health Sciences Library at Temple University, conducted specific research to identify studies on endovascular therapy and SVCS. The team of Dr. Bashir evaluated studies for several endpoints of therapy, including success rate, restenosis rate, and recurrence of SVCS after stent.
Statistical analyzes indicated that the endovascular stent was successful almost 99% of the time, with restenosis and relatively low recurrence rates. “Our analyzes really highlight the success of endovascular therapy for SVCS, proving that it is highly effective, safe, and long-lasting,” Dr. Bashir said.
Dr. Bashir and his colleagues then plan to examine the use of endovascular therapy in clinical practice. “We would like to understand more about how SVCS patients are currently treated in the United States,” he said. “Little is known about current clinical practices of SVCS, despite the severity of the disease.”
Citation: Review: the best endovascular therapy for superior vena cava syndrome (2021, June 28), retrieved June 28, 2021 at https://medicalxpress.com/news/2021-06-endovascular-therapy-superior -vena-cava.html
This document is subject to copyright. Apart from any fair treatment for the purposes of private study or research, no part may be reproduced without written permission. Content is provided for informational purposes only.